|
1
|
Komori T: The 2016 WHO Classification of
tumors of central nervous system: The major point of revision.
Neurol Med Chir. 57:301–311. 2017. View Article : Google Scholar
|
|
2
|
Chung AS, Wu X, Zhuang G, Ngu H, Kasman I,
Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al: An
interleukin-17-mediated paracrine network promotes tumor resistance
to anti-angiogenic therapy. Nat Med. 19:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Y, Xue Y, Zhang Q, Wang K, Yin J and
Lou M: Transcriptional expression of glioma chemotherapy drugs
associated marker molecules in gliomas and normal brain tissues.
Cancer Biomark. 13:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA
methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells. J Neurochem. 96:766–776. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roos WP, Batista LF, Naumann SC, Wick W,
Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells
triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Omura N, Li CP, Li A, Hong SM, Walter K,
Jimeno A, Hidalgo M and Goggins M: Genome-wide profiling of
methylated promoters in pancreatic adenocarcinoma. Cancer Biol
Ther. 7:1146–1156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W,
Tamboli P, Wood CG and Wu X: Hsa-miR-9 methylation status is
associated with cancer development and metastatic recurrence in
patients with clear cell renal cell carcinoma. Oncogene.
29:5724–5728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song Y, Mu L, Han X, Li Q, Dong B, Li H
and Liu X: MicroRNA-9 inhibits vasculogenic mimicry of glioma cell
lines by suppressing Stathmin expression. J Neurooncol.
115:381–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song Y, Mu L, Han X, Liu X and Fu S: siRNA
targeting stathmin inhibits invasion and enhances chemotherapy
sensitivity of stem cells derived from glioma cell lines. Acta
Biochim Biophys Sin (Shanghai). 46:1034–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krichevsky AM, Sonntag KC, Isacson O and
Kosik KS: Specific microRNAs modulate embryonic stem cell-derived
neurogenesis. Stem Cells. 24:857–864. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shibata M, Kurokawa D, Nakao H, Ohmura T
and Aizawa S: MicroRNA-9 modulates cajal-retzius cell
differentiation by suppressing Foxg1 expression in mouse medial
pallium. J Neurosci. 41:10415–10421. 2008. View Article : Google Scholar
|
|
14
|
Otaegi G, Pollock A, Hong J and Sun T:
MicroRNA miR-9 modifies motor neuron columns by a tuning regulation
of FoxP1 levels in developing spinal cords. J Neurosci. 31:809–818.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonev B, Pisco A and Papalopulu N:
MicroRNA-9 reveals regional diversity of neural progenitors along
the anterior-posterior axis. Dev Cell. 20:19–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X,
Lin J, Chen N and Fan Q: NF-kappaB P50/P65 hetero-dimer mediates
differential regulation of CD166/ALCAM expression via interaction
with micoRNA-9 after serum deprivation, providing evidence for a
novel negative auto-regulatory loop. Nucleic Acids Res.
39:6440–6455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Myatt S, Wang J, Monteiro L, Christian M,
Ho KK, Fusi L, Dina RE, Brosens JJ, Chaem-Maghami S and Lam EW:
Definition of microRNAs that repression expression of the tumor
suppressor gene FOXO1 in endometrial cancer. Cancer Res.
70:367–377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wan H, Guo L, Liu T, Liu M, Liu X and Tang
H: Regulation of the transcription factor NF-κB1 by microRNA-9 in
human gastric adenocarcinoma. Mole Cancer. 9:162010. View Article : Google Scholar
|
|
19
|
Laios A, O'Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mole Cancer. 7:352008. View Article : Google Scholar
|
|
20
|
Nass D, Rosenwald S, Meiri E, Gilad S,
Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A,
Kharenko O, et al: MiR-92b and miR-9/9* are specifically expressed
in brain primary tumors and can be used to differentiate primary
from metastatic brain tumors. Brain Pathol. 19:375–383. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schraivogel D, Weimann L, Beier D,
Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier
CP, et al: CAMTA1 is a novel tumour suppressor regulated by
miR-9/9* in glioblastoma stem cells. EMBOJ. 30:4309–4322. 2011.
View Article : Google Scholar
|
|
22
|
Ben-Hamo R and Efroni S: Gene expression
and network-based analysis reveals a novel role for hsa-miR-9 and
drug control over the p38 network in glioblastoma multiforme
progression. Genome Med. 3:772011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: A review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nitiss JL: Targeting DNA topoisomerase II
in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galli R, Binda E, Orfanelli U, Cipelletti
B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi
A: Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong Y, Sang M, Shang C, Xue YX and Liu
YH: Quantitative analysis of topoisomerase II alpha and evaluation
of its effects on cell proliferation and apoptosis in glioblastoma
cancer stem cells. Neurosci Lett. 518:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arivazhagan A, Kumar DM, Sagar V, Patric
IR, Sridevi S, Thota B, Srividya MR, Prasanna K, Thennarasu K,
Mondal N, et al: Higher topoisomerase 2 alpha gene transcript
levels predict better prognosis in GBM patients receiving
temozolomide chemotherapy: Identification of temozolomide as a
TOP2A inhibitor. J Neurooncol. 107:289–297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qi XC, Xie DJ, Yang QF, Wang YR, Zhu YX,
Qian C and Yang SX: LRG1 dictates the chemo-sensitivity of
temzolomide in U251 glioblastoma cells via downregulation of
EGFR/topoisomerase-2/bcl-2. Biochem Biophys Res Commun.
437:565–572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wong HY, Tsai KD, Liu YH, Yang SM, Chen
TW, Cherng J, Chou KS, Chang CM, Yao BT and Cherng JM: Cinnamomum
verum component 2-Methoxycinnamaldehyde: A novel anticancer agent
with both anti-topoisomerase I and II activities in human lung
adenocarcinoma A549 cells in vitro and in vivo. Phytother Res.
30:331–340. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boland MP, Fitzgerald KA and O'Neill LA:
Topoisomerase II required for mitoxantrone to signal nuclear factor
κB activation in HL60 cells. J Biol Chem. 275:25231–25238. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X,
Zhu Y and Yang P: The effects and molecular mechanisms of MiR-106a
in multidrug resistance reversal in human glioma U87/DDP and U251/G
cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
|
